Kardigan
United States · Biotech · Healthtech
Kardigan develops cardiovascular medicines that target specific biological drivers of heart disease and the patient groups most likely to respond.
Product
Kardigan combines cardiovascular biology, patient data and clinical development to design treatments for defined forms of heart disease. Its approach seeks to connect a disease mechanism with the patients most likely to benefit, rather than treating cardiovascular conditions as one broad category.
Its advanced programs address genetic dilated cardiomyopathy, calcific aortic valve stenosis and acute severe hypertension. The portfolio includes medicines licensed from other developers, with dedicated clinical programs intended to establish their use in these patient populations.
Funding history
2 rounds · 2 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series B | $254M | ARCH Venture Partners — ParticipantFidelity Management & Research Company — ParticipantSequoia Heritage — ParticipantT. Rowe Price Investment Management — Participant | |
| Series A | $300M | ARCH Venture Partners — LeadPerceptive Advisors — LeadSequoia Heritage — Lead |